Antibiotic Therapy and Early Onset Sepsis

NeoReviews

Volumn 13, Issue 2, 2012, Pages

  Falciglia, Gustave ^a   Hageman, Joseph R ^b,c   Schreiber, Michael ^d   Alexander, Kenneth ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861403646     PISSN: None     EISSN: 15269906     Source Type: Journal    
DOI: 10.1542/neo.13-2-e86     Document Type: Article

References (28)

1. McCracken GH Jr. Group B streptococci: the new challenge in neonatal infections. J Pediatr. 1973;82(4):703-706
2. Puopolo KM. Epidemiology of neonatal early-onset Sepsis. NeoReviews. 2008;9(12):e571-e579
3. Philip AGS. Neonatal meningitis in the new millennium. Neo- Reviews. 2003;4(3):e73-e80
4. Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med. 2002;347(4):240-247
5. Nizet V, Klein J. Remington and Klein: Infectious Disease of the Fetus and Newborn, 7th ed. New York, NY: Elsevier; 2010:223-234
6. Stoll BJ, Hansen NI, Higgins RD, et al; National Institute of Child Health and Human Development. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J. 2005;24(7): 635-639
7. Zaidi AK, Thaver D, Ali SA, Khan TA. Pathogens associated with sepsis in newborns and young infants in developing countries. Pediatr Infect Dis J. 2009;28(suppl 1):S10-S18
8. Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG. Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics. 2008;121(4):689-696
9. Puopolo KM, Eichenwald EC. No change in the incidence of ampicillin-resistant, neonatal, early-onset sepsis over 18 years. Pediatrics. 2010;125(5). Available at: www.pediatrics.org/cgi/content/full/125/5/e1031
10. Schrag SJ, Hadler JL, Arnold KE, Martell-Cleary P, Reingold A, Schuchat A. Risk factors for invasive, early-onset Escherichia coli infections in the era of widespread intrapartum antibiotic use. Pediatrics. 2006;118(2):570-576
11. Daley AJ, Isaacs D; Australasian Study Group for Neonatal Infections. Ten-year study on the effect of intrapartum antibiotic prophylaxis on early onset group B streptococcal and Escherichia coli neonatal sepsis in Australasia. Pediatr Infect Dis J. 2004;23(7): 630-634
12. Garland SM, Cottrill E, Markowski L, et al; Australasian Group for Antimicrobial Resistance-GBS Resistance Study Group. Antimicrobial resistance in group B streptococcus: the Australian experience. J Med Microbiol. 2011;60(pt 2):230-235
13. Stoll BJ, Hansen NI, Sánchez PJ, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics. 2011;127(5):817-826
14. Towers CV, Briggs GG. Antepartum use of antibiotics and early-onset neonatal sepsis: the next 4 years. Am J Obstet Gynecol. 2002;187(2):495-500
15. Chirico G, Barbieri F, Chirico C. Antibiotics for the newborn. J Matern Fetal Neonatal Med. 2009;22(suppl 3):46-49
16. Muller-Pebody B, Johnson AP, Heath PT, Gilbert RE, Henderson KL, Sharland M; iCAP Group (Improving Antibiotic Prescribing in Primary Care). Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed. 2011;96(1):F4-F8
17. Maayan-Metzger A, Barzilai A, Keller N, Kuint J. Are the "good old" antibiotics still appropriate for early-onset neonatal sepsis? A 10 year survey. Isr Med Assoc J. 2009;11(3):138-142
18. Gladwin M, Trattler B. Clinical Microbiology Made Ridiculously Simple. 3rd ed. Miami, FL; Medmaster; 2004:114-132
19. Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria: a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci. 2008;15(1):5-14
20. Fanos V, Cuzzolin L, Atzei A, Testa M. Antibiotics and antifungals in neonatal intensive care units: a review. J Chemother. 2007;19(1):5-20
21. Thaver D, Ali SA, Zaidi AK. Antimicrobial resistance among neonatal pathogens in developing countries. Pediatr Infect Dis J. 2009;28(suppl 1):S19-S21
22. Brodersen R, Robertson A. Ceftriaxone binding to human serum albumin: competition with bilirubin. Mol Pharmacol. 1989; 36(3):478-483
23. US Food and Drug Administration. Drug safety. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084263.htm. Accessed June 21, 2011
24. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics. 2006;117(1):67-74
25. Benjamin DK Jr, DeLong ER, Steinbach WJ, Cotton CM, Walsh TJ, Clark RH. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics. 2003;112(3 pt 1):543-547
26. Bizzarro MJ, Gallagher PG. Antibiotic-resistant organisms in the neonatal intensive care unit. Semin Perinatol. 2007;31(1):26-32
27. Garges HP, Alexander KA. Pharmacology Review: Newer Antibiotics: Imipenem/cilastatin and Meropenem. NeoReviews. 2003;4(12):364e-368e
28. Isaacs D. Unnatural selection: reducing antibiotic resistance in neonatal units. Arch Dis Child Fetal Neonatal Ed. 2006;91(1): F72-F74